Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DILTIAZEM HCL

All products: general benefit

Other products in the same Health Canada class (C08D) — coverage varies; not interchangeable

  • Verapamil (Isoptin): general benefit, Not a benefit

Tiazac XC · DIN 02256738 · 120mg · extended release tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Tiazac XC · DIN 02256738 Manufacturer: Biovail Pharmaceuticals Canada; listing date 2005-05-25 Health Canada: Marketed since 2021-06-04 · brand TIAZAC XC · ATC C08DB01 DILTIAZEM · form Tablet (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Tiazac XC: Formulary list price $1.0911/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0911 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74195 · Verify on the e-Formulary ↗ (DIN 02256738)

Source record
DIN 02256738: Tiazac XC Raw flags: chronicUseMed=Y, sec3=Y Item: 240400161; group id 280; item number 0583; lccId None; manufacturer id BIO Source form: ER Tab; strength: 120mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.0911; ministry $1.0911 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256738 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74195
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

VERAPAMIL HCL

· 6 products · Listed, not a benefit (2), General benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 80mg, 120mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: stable angina
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) • Chronic Stable Angina NORVASC is indicated for the management of chronic stable angina (effort-associated angina) in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS AA-DILTIAZ (diltiazem hydrochloride) is indicated for: • Angina ▪ AA-DILTIAZ (diltiazem hydrochloride) tablets may be used in the management of angina resulting from coronary artery spasm. ▪ AA-DILTIAZ tablets are indicated for the management of chronic stable angina (effort- associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. AA-DILTIAZ tablets may be tried in combination with beta-blockers in chronic stable angina in patients with normal ventricular function. When such concomitant therapy is introduced, patients must be monitored closely (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular). ▪ AA-DILTIAZ tablets may be useful in unstable angina when spasm of the coronary vessels is definitely a contributing factor (e.g., ST segment elevation). In the absence of objective evidence of a spastic component, nitrates or nitrates plus a beta-blocker are at present the treatment of choice. If, in the… https://pdf.hres.ca/dpd_pm/00082380.PDF PM date: DEC 31, 1988 Source product: AA-DILTIAZ; DIN 00771376; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.